Terazosin

Alpha-adrenoceptor blocker:Hypertension Benign prostatic hyperplasia (BPH)

Hypertension: 1–20 mg once daily BPH: 1–10 mg once daily

Molecular weight :459.9

%Protein binding :90–94

%Excreted unchanged in urine : 10

Volume of distribution (L/kg) :0.5–0.9

half-life – normal/ESRD (hrs) :9–12/Unchanged

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Antidepressants: enhanced hypotensive effect with MAOIs

Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Moxisylyte: possibly severe postural hypotension when used in combination

Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use

–

Oral

–

–

Therapy should be initiated with a single dose of 1 mg given at bedtime.